Making earlier cancer detection a routine part of medical care

Working to bring the best multi-cancer test to patients Presented data at ESMO 4 biomarker classes 61% 98.2% sensitivity specificity 11 of 15 organ types detected have no screening option methylation EXACT SCIENCES protein mutation aneuploidy Source: Douville et al., ESMO congress poster (2022); we expect our multi-cancer test to detect dozens of cancers when measured by all subtypes included Upcoming milestones Feasibility data X X X X Early-access program to generate evidence Clinical validation data Finalize test design Begin prospective study 10

View entire presentation